header image



Minerva Foundation Institute for Medical Research


Minerva Foundation Institute for Medical Research is a private institute in biomedicine that is located at Biomedicum Helsinki in close association with Helsinki University in a large congolomerate of modern laboratories with research groups in the biomedical and medical research fields. At Minerva about 40 persons including scientists, PhD students and technical assistants are actively working in nine research groups. General theme of the research is the study of basic cellular and molecular mechanisms underlying important human diseases, including heart and cardiovascular diseases, diabetes and neurological disorders.

Read more about MINERVA FOUNDATION


News and Forthcoming Events


8/2019 - Award Ceremony
MEDIX PRIZE OF THE MINERVA FOUNDATION 2019

Award Ceremony and Prize Lectures on Monday, September 23, 2019 at 13:15 - 15:00.
Biomedicum Helsinki 1, Lecture Hall 2, Haartmaninkatu 8, 00290 Helsinki

The Medix prize is awarded annually for an excellent Finnish scientific study published as one article during the previous year. To celebrate the 60th anniversary of Minerva Foundation two Medix Prizes are awarded year 2019, each 20.000€. One of the prizes is awarded for a study of clinical medicine and the other for biomedical basic research.


6/2019 -Thesis Award
THESIS AWARD 2018 TO PANU LUUKKONEN

Lääkärilehti has awarded Panu Luukkonen, M.D., D.Med.Sci, for the best thesis 2018. Title for the thesis is 'Heterogeneity of Non-Alcoholic Fatty Liver Disease – Genetic and Nutritional Modulation of Hepatic Lipid Metabolism'.

READ MORE – IN FINNISH


5/2019 - Academy of Finland Project Funding

Academy of Finland has granted a 4-year Academy project funding to Professor Vesa Olkkonen. The funding period is from 2019 to 2023 and the funding in total 533 706€. The project title is ‘Membrane contact sites in endothelial cells (EC): Novel lipid transport and signaling platforms for EC activation and angiogenesis’.

Vesa Olkkonen

Project description
: Endothelial cell (EC) dysfunction plays key roles in major human diseases such as cardiovascular diseases (CVDs) and cancers. Metabolic fluxes and signaling events within cells are organized in an integrated manner allowing high efficiency and capacity transfer of lipids, ions and signals between cell organelles. Organelles related functionally are physically connected via membrane contact sites (MCSs). The aim of this proposal is to identify MCSs and their components with key roles in select EC functions crucial for atherosclerotic CVDs, EC activation and angiogenesis. We launch a systematic study of MCS component expression and regulation in ECs – followed by detailed analysis of the function and pathophysiological role of select MCSs and their protein components. The work produces break-throughs in understanding the roles of MCSs in human diseases characterized by endothelial dysfunction such as CVDs, resulting in the identification of new therapy targets.

LIPID SIGNALING AND HOMEOSTASIS


3/2019 -Novo Nordisk Postdoctoral Fellowship

NOVO NORDISK FOUNDATION CELEBRATES TALENTED YOUNG RESERCHERS

The Novo Nordisk Foundation has awarded postdoctoral fellowship to Panu Luukkonen, M.D., D.Med.Sci. The grant amount is 4,00,000 DKK. Luukkonen's project title is 'Heterogeneity of Non-Alcoholic Fatty Liver Disease in Humans' and the research is done in Yale University School of Medicine, New Haven, CT, USA and Minerva Foundation Institute for Medical Research, Helsinki, Finland.

Panu Luukkonen

Project description: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting up to 1 in 4 of the Western population, and predisposes to liver cirrhosis and cancer. Treatment options for NAFLD are scarce, of which weight loss is amongst the most effective. There are two common subtypes of NAFLD; one related to overweight and one to genetics. For unknown reason, the former but not the latter is associated with insulin resistance that precedes type 2 diabetes and heart disease. In Project 1, we will comprehensively assess the effect of weight loss on liver fat and carbohydrate metabolism in the two subtypes of NAFLD in humans using a new state-of-the-art method by analyzing blood samples taken during infusion of safe, non-radiating tracers. In animals, insulin resistance is mediated by distinct class of lipids, diacylglycerols (DAGs). In Project 2, we study the effect and underlying mechanisms of DAGs on insulin resistance in human liver samples.

READ MORE


2/2019 – Funding from The Finnish Cultural Foundation

The Finnish Cultural Foundation has granted Docent Päivi Lakkisto a 200,000€ funding for research on ´Sydän- ja verisuonitautien yksilöllinen diagnostiikka, ennusteen arviointi ja uusien lääkehoidon kohteiden tunnistaminen transkriptomiikan keinoin’.


Päivi Lakkisto

READ MORE - IN FINNISH

CARDIOVASCULAR RESEARCH


3/2019 - Scientific Report
MINERVA SCIENTIFIC REPORT 2018



DOWNLOAD


8/2018 - Minerva Wihuri Symposium
Minerva and Wihuri Research Institutes organized a Symposium on August 28 - 29, 2018.
MINERVA AND WIHURI RESEARCH INSTITUTES SYMPOSIUM
Stem Cells in Regenerative Medicine

DOWNLOAD PROGRAM



OM FORSKNINGEN PÅ MINERVA

Medicinska forskningsinstitutet Minerva är ett privat forskningsinstitut som upprätthålls av Minervastiftelsen. Vid institutet arbetar ca 40 personer bestående av senior forskare, doktorander och teknisk personal. 9 forskningsgrupper, vars forskning syftar till att utreda medicinskt betydande sjukdomars, uppkomstmekanismer och behandlingsmöjligheter genom att utnyttja såväl kliniska som prekliniska forskningsmetoder. Sjukdomar som undersöks är bl.a. hjärt- och kärlsjukdomars, diabetes och nervsjukdomar.

LÄS MERA OM FORSKNINGEN PÅ MINERVA


MINERVAN TUTKIMUKSESTA

Lääketieteellinen tutkimuslaitos Minerva on Minervasäätiön ylläpitämä yksityinen tutkimuslaboratorio. Tutkimuslaitoksessa työskentelee n. 40 henkilöä koostuen tutkijoista, väitöskirjatyöntekijöistä sekä avustavasta henkilökunnasta. 9 tutkimusryhmää, joiden tutkimustyötä leimaa pyrkimys selvittää lääketieteellisesti merkittävien sairauksien kuten sydän- ja verisuonisairauksien, diabeteksen ja hermoston tautien syntymekanismeja ja hoitomahdollisuuksia kliinisiä ja prekliinisiä tutkimusmenetelmiä hyödyntäen.

MINERVAN TUTKIMUKSESTA SUOMEKSI

DIABETESTUTKIMUSSÄÄTIÖN KAKSIVUOTINEN SUURAPURAHA HEIKKI KOISTISELLE

AKTIININ FOSFORYLAATIO - LIMASIENTEN ERIKOISMEKANISMISTA HERMOSOLUJEN SÄÄTELIJÄKSI


Home | About the Institute | Research Groups | Administration | Contact info | Minerva News